A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Inclusion:

• Must have prostate cancer
• Have received prior castration by orchiectomy and/or hormone therapy
• Males >18 years of age
• Normal activity level for self care
• Have been receiving abiraterone therapy with a steroid for ≥1 month
• Have disease progression on abiraterone as defined by either PSA progression, radiographic or bone progression
• Have adequate bone marrow, liver and kidney function
• Must be willing to provide pre-existing tumor samples, if this material exists. If pre-existing samples are not available, a sample must be obtained during screening
• Must be willing and able to provide written informed consent and comply with the protocol and study procedures

Exclusion:

• Prior anti-cancer treatment with any Heat Shock Protein 90 (HSP90) inhibitor or histone deacetylase (HDAC) inhibitor compound
• Have received chemotherapy within 4 weeks prior to receiving study drug
• Prior prostate surgery or radiotherapy within 4 weeks from the first dose of study drug
• Hypersensitivity to AT13387 or other components of the drug product
• Treatment with any investigational drug within 4 weeks prior to the first dose of study drug
• Severe systemic diseases or active uncontrolled infections
• Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
• Abnormal heart function
• Other cancer except for adequately treated basal cell or squamous cell carcinoma of the skin, or superficial bladder cancer, or other cancer from which the subject has been disease-free for at least 3 years;
• No known brain or CNS involvement
• Unable to receive corticosteroids or history of pituitary or adrenal dysfunction
• Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus